US 12,257,299 B2
SARS-CoV-2 RNA vaccine compositions and methods of use
Steven Gregory Reed, Bellevue, WA (US); Darrick Albert Carter, Seattle, WA (US); Amit Praful Khandhar, Issaquah, WA (US); Jacob Freeman Archer, Seattle, WA (US); Lars Peter Aksel Berglund, Seattle, WA (US); Jesse Erasmus, Port Orchard, WA (US); Bryan Berube, Issaquah, WA (US); and Malcolm S. Duthie, Sammamish, WA (US)
Assigned to HDT Bio Corp., Seattle, WA (US)
Filed by HDT Bio Corp., Seattle, WA (US)
Filed on Mar. 21, 2024, as Appl. No. 18/612,698.
Application 18/612,698 is a continuation of application No. PCT/US2022/013513, filed on Jan. 24, 2022.
Claims priority of provisional application 63/297,397, filed on Jan. 7, 2022.
Claims priority of provisional application 63/247,169, filed on Sep. 22, 2021.
Prior Publication US 2024/0261393 A1, Aug. 8, 2024
Int. Cl. A61K 39/215 (2006.01); A61K 9/107 (2006.01); A61K 9/16 (2006.01); A61K 9/19 (2006.01); A61K 39/00 (2006.01); A61P 37/04 (2006.01)
CPC A61K 39/215 (2013.01) [A61K 9/1075 (2013.01); A61K 9/1617 (2013.01); A61K 9/1623 (2013.01); A61K 9/19 (2013.01); A61P 37/04 (2018.01); A61K 2039/53 (2013.01); A61K 2039/55505 (2013.01); A61K 2039/55516 (2013.01)] 30 Claims
 
1. A dried composition comprising:
a) a lipid carrier, wherein the lipid carrier is a nanoemulsion comprising a hydrophobic core, and one or more lipids;
b) at least one nucleic acid that comprises a sequence encoding a SARS-CoV-2 spike protein or a functional variant thereof, wherein the at least one nucleic acid comprises a sequence at least 85% identical to any one of SEQ ID NOS: 1-8; and
c) at least one sugar present in amount of at least about 50% by weight of the dried composition.